How earlier signals of misconnection may help pharma identify trust breakdowns before they show up as lagging measures in adherence, initiation, engagement, and outcomes.
Jewel Jones
Advertisement
Jewel Jones Truxon is EVP, Executive Director, Inclusive Health at Real Chemistry, a tier-one commercialization partner to the world's most innovative life sciences and healthcare companies. She founded the group's health equity practice and now leads the enterprise-wide Inclusive Health strategy, helping healthcare and life sciences companies ensure scientific breakthroughs reach, resonate with, and benefit the people they are intended to serve. Jewel is ajess 2026 BLOC100 honoree, an Aspen Institute Business & Society Fellow, a former PRWeek 40 Under 40 honoree, and serves on the Board of Visitors for Howard University's College of Nursing and Allied Health Sciences.
Articles by Jewel Jones
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
2
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
3
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
4
How a Shift Towards Oral Medications Impacts GLP-1s
5